Overview

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Status:
Recruiting

Trial end date:
2030-04-03

Target enrollment:

Participant gender:

Summary

Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Lenvatinib
Pembrolizumab